These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24000503)

  • 21. Long-term efficacy of imatinib for treatment of metastatic GIST.
    Patel S
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):277-86. PubMed ID: 23503753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib.
    Wilkinson MJ; Fitzgerald JE; Strauss DC; Hayes AJ; Thomas JM; Messiou C; Fisher C; Benson C; Tekkis PP; Judson I
    Br J Surg; 2015 Jul; 102(8):965-71. PubMed ID: 25970743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
    Kang YK; Kang BW; Im SA; Lee JL; Park SR; Kang WK; Chang HM; Kim TW; Oh DY; Jung KH; Ryu MH
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adherence to imatinib therapy in patients with gastrointestinal stromal tumors.
    Blay JY; Rutkowski P
    Cancer Treat Rev; 2014 Mar; 40(2):242-7. PubMed ID: 23931926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection.
    Tirumani SH; Shinagare AB; Jagannathan JP; Krajewski KM; Ramaiya NH; Raut CP
    Eur J Surg Oncol; 2014 Apr; 40(4):420-8. PubMed ID: 24238762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
    Li J; Dang YZ; Gao J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):216-20. PubMed ID: 23536338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
    Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
    J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
    Dematteo RP; Ballman KV; Antonescu CR; Maki RG; Pisters PW; Demetri GD; Blackstein ME; Blanke CD; von Mehren M; Brennan MF; Patel S; McCarter MD; Polikoff JA; Tan BR; Owzar K;
    Lancet; 2009 Mar; 373(9669):1097-104. PubMed ID: 19303137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Current aspects of treatment in gastrointestinal stromal tumors (GIST)].
    Láng I; Hitre E
    Orv Hetil; 2005 May; 146(18 Suppl 1):935-41. PubMed ID: 15921308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour.
    Machlenkin S; Pinsk I; Tulchinsky H; Ziv Y; Sayfan J; Duek D; Rabau M; Walfisch S
    Colorectal Dis; 2011 Oct; 13(10):1110-5. PubMed ID: 21040362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate].
    Haugland HK; Jebsen NL; Mannelqvist M; Skar R; Eide J; Øvrebø K; Horn A; Jensen DK; Monge OR; Lilleng PK
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):868-72. PubMed ID: 15815732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Surgical treatment for patients with advanced gastrointestinal stromal tumor after targeted therapy].
    Wang CM; Shi YQ; Ye YW; Fu H; Zhao GF; Zhou Y; DU CY; Dong RZ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Mar; 12(2):155-8. PubMed ID: 19296251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
    Wang D; Zhang Q; Blanke CD; Demetri GD; Heinrich MC; Watson JC; Hoffman JP; Okuno S; Kane JM; von Mehren M; Eisenberg BL
    Ann Surg Oncol; 2012 Apr; 19(4):1074-80. PubMed ID: 22203182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors.
    Ogata K; Mochiki E; Ojima H; Haga N; Fukuchi M; Aihara R; Ando H; Uchida N; Toyomasu Y; Suzuki M; Kimura A; Kogure N; Yokobori T; Ohno T; Kuwano H
    J Surg Oncol; 2014 Dec; 110(8):942-6. PubMed ID: 25164620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An audit of surgical management of gastrointestinal stromal tumours (GIST).
    Bucher P; Egger JF; Gervaz P; Ris F; Weintraub D; Villiger P; Buhler LH; Morel P
    Eur J Surg Oncol; 2006 Apr; 32(3):310-4. PubMed ID: 16414236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.
    Haller F; Detken S; Schulten HJ; Happel N; Gunawan B; Kuhlgatz J; Füzesi L
    Ann Surg Oncol; 2007 Feb; 14(2):526-32. PubMed ID: 17139461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.
    Zhu J; Wang Y; Hou M; Li HY; Zhang J
    Oncology; 2007; 73(5-6):324-7. PubMed ID: 18497504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial.
    Blesius A; Cassier PA; Bertucci F; Fayette J; Ray-Coquard I; Bui B; Adenis A; Rios M; Cupissol D; Pérol D; Blay JY; Le Cesne A
    BMC Cancer; 2011 Feb; 11():72. PubMed ID: 21324142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Indications for pre- and postoperative treatment with imatinib for gastrointestinal stromal tumors].
    Heger U; Weitz J; Lordick F
    Chirurg; 2008 Jul; 79(7):630-7. PubMed ID: 18548219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.